Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Rochester
With
National Cancer Institute (NCI)
OBJECTIVES:
* Evaluate the effect of androgen ablation on bone resorption in patients with or without bone metastases secondary to prostate cancer.
OUTLINE: Patients are stratified according to prior androgen ablation therapy (yes vs no) and metastatic disease (yes vs no).
Patients undergo blood work and 24 hour urine collection on day 1 and at week 6-8. Patients who have received androgen ablation therapy and are found to have increased bone resorption undergo a dual energy x-ray absorptiometry (DEXA) scan.
A comparison is made between androgen ablation therapy and bone resorption and if metastases are associated with the two.
PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study within 9 months.
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Histologically confirmed prostate cancer
Stratum 1 (androgen ablation therapy):
* Bone metastases
* Prior orchiectomy allowed
* Prior or concurrent leuprolide and/or goserelin therapy allowed
Stratum 2 (androgen ablation therapy):
* No bone metastases
* Prior orchiectomy allowed
* Prior or concurrent leuprolide and/or goserelin therapy allowed
Stratum 3 (no androgen ablation therapy):
* No metastatic disease
* Prior flutamide or bicalutamide therapy allowed
PATIENT CHARACTERISTICS:
Age:
Not specified
Performance status:
Not specified
Life expectancy:
Not specified
Hematopoietic:
Calcium normal
Hepatic:
Not specified
Renal:
Not specified
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Not specified
Chemotherapy:
See Disease Characteristics
Endocrine therapy:
See Disease Characteristics
No concurrent high dose steroids
Radiotherapy:
Prior radiotherapy allowed
Surgery:
See Disease Characteristics
Prior radical prostatectomy allowed
Other:
No concurrent bisphosphonates
Clareo Health | Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer
